Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Triple Negative Breast Cancer Team Project
Team Project

Triple Negative Breast Cancer Team Project

333
Anderson, KarenArizona State University
Anderson, KarenArizona State University
40 biomarkers: 1   NADH dehydrogenase 1a subcomplex, 10      NDUFA10 2   Protein-tyrosine phosphatase, mitochondrial 1      PTPMT1 3   Integrin beta-1      ITGB1 4   Mast/stem cell growth factor receptor      KIT 5   DNA-directed RNA polymerase L, 7.6 kDa      POLR2L 6   Ephrin-A5      EFNA5 7   Regulator of G-protein signaling 5      RGS5 8   TNFR superfamily member 6 (Ab1)      FAS 9   Stomatin-like protein 2      STOML2 10   Signal transducer /activator of transcription 6      STAT6 11   Cysteine-rich protein 2 
Proteomics
Breast and Gynecologic Cancers Research
1

Triple negative breast cancers (TNBC), comprise 15-20% of breast cancers, and are associated with later stage at diagnosis, increased mortality, and occur more frequently in younger women where mammographic screening is less reliable. TNBCs are more likely to be diagnosed by physical exam than by mammographic screening. There is an unmet clinical need for biomarkers for the early detection of TNBC. Here, we are proposing the development of a plasma-based biomarker panel for the routine screening of women over the age of 40 for TNBC that can be used to identify women for further imaging.

The overall study design involves the identification of three distinct types of blood-based biomarkers: 1. Autoantibodies (Anderson/LaBaer) 2. Protein antigens (Li/Lampe; Zangar). 3. miRNA (Huebner/Croce). These biomarkers will be validated in a step-wise fashion using samples provided by the CEVCs and multi-institutional cohorts, with study design and evaluation by the DMCC. Aim 1. Verification of novel biomarkers for TNBC Aim 2. Validate the top biomarkers for TNBC using a diagnostic set of plasma. Aim 3. Determine the sensitivity, specificity, and positive predictive value of the top marker combinations found in aim 2 to distinguish TNBC from benign breast disease, and for the detection of ER+ and Her2+ breast cancer, using the EDRN Reference Set. Aim 4. Develop a phase III validation plan for testing the top biomarkers and biomarker combination for TNBC detection using prediagnostic sera from WHI, ROCA, and PLCO.
We will systematically compare existing TNBC biomarkers that have been identified from multiple laboratories, targeting protein antigens, autoantibodies, and miRNAs. These biomarkers will be validated in a step-wise fashion using samples provided by the CEVCs and multi institutional cohorts, with study design and evaluation by the DMCC. The individual and composite sensitivities and specificities of these biomarkers for the detection of TNBC and non-TNBC breast cancers will be evaluated. These studies will lead to the development of a phase III validation plan for testing the top biomarkers and biomarker combination for TNBC detection using prediagnostic sera from WHI, ROCA, and PLCO.

No datasets are currently associated with this protocol.


Announcement 7/2/2018

The 33rd EDRN Steering Committee Meeting is from September 5-6, 2018 in Boston, MA. Please click here for meeting registration and hotel information.

Announcement 6/1/2018

Dr. Sudhir Srivastava was honored with the 2017 Human Proteome Organization (HUPO) Award for a Distinguished Scientist in Clinical and Translational Proteomics. Please join us in congratulating him on his accomplishments and contributions. The awards were presented at HUPO 2017 in Dublin, Ireland and the winners were present to provide a small talk during the Awards Ceremony and HUPO Lectures.